BMY-25271
| 中文名称 | BMY-25271 |
|---|---|
| 中文同义词 | 化合物 T10575 |
| 英文名称 | N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide |
| 英文同义词 | BMY-25271;N-[2-[[[5-[(Dimethylamino)methyl]furan-2-yl]methyl]thio]ethyl]-1,2,5-thiadiazole-3,4-diamine1-oxide;1,2,5-Thiadiazole-3,4-diamine, N3-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-, 1-oxide;BMY25271,BMY 25271 |
| CAS号 | 78441-82-4 |
| 分子式 | C12H19N5O2S2 |
| 分子量 | 329.44 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 78441-82-4.mol |
| 结构式 |  |
BMY-25271 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
BMY-25271 是一个组胺 H2 受体 (histamine H2 receptor) 拮抗剂。
Histamine H2 receptor
BMY-25271 is a histamine H2 receptor antagonist. The dose response curves are parallel and oral ED 50 values derived from probit analysis are 0.093, 0.97 and 6.9 mg/kg for BMY-25271, ranitidine and cimetidine, respectively. BMY-25271, therefore, is about 10 and 74 times more potent than ranitidine and cimetidine, respectively. Pretreatment with the highest dose of BMY-25271 does not significantly affect the absorption of aspirin or the formation of its major metabolite, salicylic acid.